<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03810612</url>
  </required_header>
  <id_info>
    <org_study_id>2015/57</org_study_id>
    <nct_id>NCT03810612</nct_id>
  </id_info>
  <brief_title>Patient-reported Outcomes After Percutaneous Coronary Intervention</brief_title>
  <acronym>CONCARD</acronym>
  <official_title>Continuity of Care, Adherence to Treatment and Self-reported Health After Percutaneous Coronary Intervention (CONCARD): a Patient-centered Care Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Herlev and Gentofte Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Western Norway University of Applied Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to investigate i) continuity of care, ii) health literacy and&#xD;
      self-management, iii) adherence to treatment, and iv) patient preferences, healthcare&#xD;
      utilization and costs, and to determine associations with future short- and long-term health&#xD;
      outcomes in patients after percutaneous coronary intervention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CONCARD will use multiple designs. (1) An inductive exploratory design including in-depth&#xD;
      interviews on patients' experiences of healthcare delivery will provide a context for the&#xD;
      quantitative data to develop the content of the cohort study and trial intervention. (2) A&#xD;
      prospective cohort design with a 1-year follow-up period will include data on&#xD;
      patient-reported outcomes, and a 10-year follow-up for adverse events. In translation and&#xD;
      adaptation of patient-reported outcome measures, a methodological design will be applied. (3)&#xD;
      A discrete choice experiment will investigate patient preferences for aftercare and cardiac&#xD;
      rehabilitation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2017</start_date>
  <completion_date type="Anticipated">May 2030</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Continuity of care</measure>
    <time_frame>2 months</time_frame>
    <description>The Heart Continuity of Care Questionnaire (HCCQ) comprises 33 items covering eight topic areas regarding continuity of care. Respondents rate each item on a 6-point scale ranging from 1 (strongly disagree) to 5 (strongly agree) or 6 (not applicable).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of the quality of healthcare delivery</measure>
    <time_frame>2 months</time_frame>
    <description>The Nordic Patient Experiences Questionnaire (NORPEQ) comprises 8 items and gives a brief measure of patient experiences in evaluation of the quality of healthcare delivery. Respondents rate each item on a 5-point scale ranging from 1 (not at all) to 5 (to a large extent). Six of the eight NORPEQ items sum to produce an overall scale from 0 to 100, where 100 is the best possible experience of care.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in eHealth literacy</measure>
    <time_frame>2 months, 12 months</time_frame>
    <description>The eHealth Literacy Scale (Eheals) is an 8-item measure of eHealth literacy developed to measure consumers' combined knowledge, comfort, and perceived skills at finding, evaluating, and applying electronic health information to health problems. Respondents indicate their agreement with statements on a 5-point Likert scale ranging from 1 (Strongly Disagree) to 5 (Strongly agree).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in health literacy</measure>
    <time_frame>2 months, 12 months</time_frame>
    <description>The Health literacy questionnaire (HLQ) has nine scale scores that each measure an aspect of the multidimensional construct of health literacy. Each score provides insight into the strengths and limitations of the respondent, but the scores are most powerful when viewed together to show the 'health literacy profile' of the respondent.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient knowledge, skill, and confidence for self-management.</measure>
    <time_frame>6 months</time_frame>
    <description>The Patient Activation Measure (PAM-13) comprises 13 items assessing patient knowledge, skill and confidence for self-management. Respondents indicate their agreement with statements on a 5-point Likert scale ranging from 1 (Strongly Disagree) to 4 (Strongly agree), or 5 (not applicable). Patients with a high activation score were associated with fewer mental health symptoms, greater recovery attitudes and medication adherence.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in beliefs and perceptions about medicines and treatment</measure>
    <time_frame>2 months, 6 months, 12 months</time_frame>
    <description>The Beliefs about Medicines Questionnaire (BMQ) assesses beliefs and perceptions about medicines and treatment. The BMQ comprises two sections: the BMQ-Specific which assesses representations of medication prescribed for personal use and the BMQ-General which assesses beliefs about medicines in general. The two sections of the BMQ can be used in combination or separately. For this study, the BMQ-Specific will be used. Respondents rate 11 items on a 5-point scale ranging from 1 (strongly agree) to 5 (strongly disagree).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in self-reported adherence to medicines</measure>
    <time_frame>2 months, 6 months, 12 months</time_frame>
    <description>The Medication Adherence Report Scale (MARS-5) measures self-reported adherence to medicines, it assesses both intentional and unintentional non-adherence. Respondents indicate their agreement with statements about their medicine use on a 5 point Likert scale ranging from 1 (always) to 5 (never).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in medication use</measure>
    <time_frame>2 months, 6 months, 12 months</time_frame>
    <description>Data related to consumption of prescribed medication are identified through national prescription registries. The registries cover all prescriptions dispensed at pharmacies nationwide. The registries also include information about date of dispensation, quantity and strength dispensed. This will serve as complimentary information to patients' self-reported adherence.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health care utilization</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Healthcare utilization will be assessed during follow-up, including patients' use of primary care services (general practitioner visits) and secondary care services (inpatient admissions and outpatient visits). The data source will be nationwide registries. The measurement unit will be mean number of visits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health care (associated) costs</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Health care (associated) costs will be valued using the tariffs of national agreements between the professional associations of medical specialists and the National Health Services. In secondary care, inpatient admissions and outpatient visits will be valued using the tariffs of the national case-mix system of the diagnosis-related groupings (DRG) and the ambulatory grouping system (DAGS). In addition, data will be collected on prescription of medication, which will be valued using the retail price. The data source will be nationwide registries. The measurement unit will be mean costs in Euros.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to readmission to hospital</measure>
    <time_frame>30-days, 3 months, 6 months, 12 months, up to 10 years</time_frame>
    <description>Cardiac and all cause readmissions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death</measure>
    <time_frame>30-days, 3 months, 6 months, 12 months, up to 10 years</time_frame>
    <description>Cardiac and all cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anxiety and depression</measure>
    <time_frame>2 months, 6 months, 12 months</time_frame>
    <description>The Hospital Anxiety and Depression Scale (HADS). The HADS is a fourteen item scale where seven of the items relate to anxiety and seven relate to depression. The respondent rates each item on a 4-point scale ranging from 0 (absence) to 3 (extreme presence). The total score is 42 (21 per subscale).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in self-reported health</measure>
    <time_frame>2 months, 6 months, 12 months</time_frame>
    <description>EQ-5D-5L is an 5 item (plus a VAS scale) self-report-questionnaire assessing self-reported health. Each question has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in chest pain</measure>
    <time_frame>2 months, 6 months, 12 months</time_frame>
    <description>The Seattle Angina Questionnaire (SAQ-7) comprises 7 dimensions of coronary artery disease. Each scale is transformed to a score of 0 to 100, where higher scores indicate better function (eg, less physical limitation, less angina, and better quality of life).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fatigue</measure>
    <time_frame>2 months, 6 months,12 months</time_frame>
    <description>A visual analog scale ranging from 0 (fatigue is not a problem) to 10 (fatigue is a major problem) is used to measure change in fatigue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frailty status</measure>
    <time_frame>12 months</time_frame>
    <description>The Study of Osteoporotic Fractures (SOF) index will be used to measure frailty status. The SOF index includes three items: 1) weight loss &gt; 5% in the last year, 2) inability to rise from a chair five times without using arms, and 3) reduced energy level. The questions have dichotomous response alternatives (yes/no). Patients who meet none of these criteria will be considered robust, one of the criteria are pre-frail, and two or three of these criteria are considered frail.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient preferences in discrete choice experiments</measure>
    <time_frame>3 months</time_frame>
    <description>A discrete choice experiment (DCE) is a quantitative technique for eliciting preferences to be used in the absence of revealed preference data. This involves asking individuals to state their preference over hypothetical alternative scenarios. Each alternative is described by several attributes which are used to determine if preferences are significantly influenced by these. No standardized measurement tool is used in DCE. The alternative scenarios (attributes) are developed for each individual study. Therefore, a DCE will be undertaken as a cross-sectional survey to investigate the preferences for aftercare. Participants are asked to choose between hypothetical aftercare programs described by five key characteristics that varies across each of the respondents' choices. The DCE will be carried out according to recommendations by the ISPOR group. A multinomial mixed logit model are used to model preferences and calculate marginal rates of substitution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>The HeartQoL questionnaire is a core ischemic heart disease specific health related quality of life (HRQL) questionnaire. The questionnaire comprises 14-items with 10-item physical and 4-item emotional subscales which are scored from 0 (poor HRQL) to 3 (better HRQL) with a global score if needed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in physical and mental dimensions of health.</measure>
    <time_frame>2 months, 6 months, 12 months</time_frame>
    <description>RAND-12 measures physical and mental dimensions of health. The 12 items in the questionnaire correspond to eight principal physical and mental health domains. The 12 items are summarized into two scores, a &quot;Physical Health Summary Measure {PCS-physical component score}&quot; and a &quot;Mental Health Summary Measure {MCS-mental component score}&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health status following myocardial infarction</measure>
    <time_frame>2 months, 6 months, 12 months</time_frame>
    <description>The Myocardial Infarction Dimensional Assessment Scale (MIDAS) is a PRO measure developed and validated to specifically measure the health status of individuals who have suffered a myocardial infarction. It consist of 7 domains, and is a 35 item scale where respondents rate each item on a 5-point scale ranging from 1 (never) to 5 (always). The function of the MIDAS is to indicate the extent of ill health in each of the seven domains assessed, therefore each dimension is scored separately using a simple scoring methodology.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Coronary Artery Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have undergone percutaneous coronary intervention will be included&#xD;
        prospectively at each percutaneous coronary intervention centre.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing percutaneous coronary intervention&#xD;
&#xD;
          -  ≥ 18 years of age&#xD;
&#xD;
          -  Living at home at the time of inclusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who do not speak Norwegian/Danish&#xD;
&#xD;
          -  Patients who are unable to fill in the questionnaires due to reduced capacities&#xD;
&#xD;
          -  Institutionalized patients&#xD;
&#xD;
          -  Patients with expected lifetime less than one year&#xD;
&#xD;
          -  Percutaneous coronary intervention without stent implantation&#xD;
&#xD;
          -  Patients undergoing percutaneous coronary intervention related to Transcatheter Aortic&#xD;
             Valve Implantation or Mitraclip examination&#xD;
&#xD;
          -  Previous enrollment in CONCARD (readmissions).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tone M Norekvål, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haukeland University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tone M Norekvål, PhD</last_name>
    <phone>+4799044635</phone>
    <email>tone.merete.norekval@helse-bergen.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nina B Fålun, MSc</last_name>
    <phone>+4790858527</phone>
    <email>nina.falun@helse-bergen.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Herlev and Gentofte Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>1092</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pernille P Johansen, PhD</last_name>
      <phone>+4525361356</phone>
      <email>pernille.palm.johansen@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Britt Borregaard, MSc</last_name>
      <phone>+4526661136</phone>
      <email>Britt.Borregaard@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zealand University Hospital</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina B Hansen, PhD</last_name>
      <phone>+4528309754</phone>
      <email>tbh@regionsjaelland.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tone M Norekvål, PhD</last_name>
      <phone>+4799044635</phone>
      <email>tone.merete.norekval@helse-bergen.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital, Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bjørn Bendz, PhD</last_name>
      <phone>+4795802582</phone>
      <email>bbendz@ous-hf.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <zip>4068</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alf Inge Larsen, PhD</last_name>
      <phone>+4795889896</phone>
      <email>alf.inge.larsen@sus.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Norway</country>
  </location_countries>
  <link>
    <url>https://helse-bergen.no/en/procard/projects-in-procard/concard-pci</url>
    <description>Study website</description>
  </link>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>December 21, 2018</study_first_submitted>
  <study_first_submitted_qc>January 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2019</study_first_posted>
  <last_update_submitted>January 17, 2019</last_update_submitted>
  <last_update_submitted_qc>January 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adherence to treatment</keyword>
  <keyword>Continuity of care</keyword>
  <keyword>Health literacy</keyword>
  <keyword>Patient involvement</keyword>
  <keyword>Patient preferences</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>Rehabilitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03810612
org study id: 2015/57
nct id: NCT03810612
lead sponsor: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
The main objective is to investigate i) continuity of care, ii) health literacy and
      self-management, iii) adherence to treatment, and iv) patient preferences, healthcare
      utilization and costs, and to determine associations with future short- and long-term health
      outcomes in patients after percutaneous coronary intervention.
CONCARD will use multiple designs. (1) An inductive exploratory design including in-depth
      interviews on patients' experiences of healthcare delivery will provide a context for the
      quantitative data to develop the content of the cohort study and trial intervention. (2) A
      prospective cohort design with a 1-year follow-up period will include data on
      patient-reported outcomes, and a 10-year follow-up for adverse events. In translation and
      adaptation of patient-reported outcome measures, a methodological design will be applied. (3)
      A discrete choice experiment will investigate patient preferences for aftercare and cardiac
      rehabilitation.
observational model: Cohort
time perspective: Prospective
measure: Continuity of care
time frame: 2 months
description: The Heart Continuity of Care Questionnaire (HCCQ) comprises 33 items covering eight topic areas regarding continuity of care. Respondents rate each item on a 6-point scale ranging from 1 (strongly disagree) to 5 (strongly agree) or 6 (not applicable).
measure: Evaluation of the quality of healthcare delivery
time frame: 2 months
description: The Nordic Patient Experiences Questionnaire (NORPEQ) comprises 8 items and gives a brief measure of patient experiences in evaluation of the quality of healthcare delivery. Respondents rate each item on a 5-point scale ranging from 1 (not at all) to 5 (to a large extent). Six of the eight NORPEQ items sum to produce an overall scale from 0 to 100, where 100 is the best possible experience of care.
measure: Change in eHealth literacy
time frame: 2 months, 12 months
description: The eHealth Literacy Scale (Eheals) is an 8-item measure of eHealth literacy developed to measure consumers' combined knowledge, comfort, and perceived skills at finding, evaluating, and applying electronic health information to health problems. Respondents indicate their agreement with statements on a 5-point Likert scale ranging from 1 (Strongly Disagree) to 5 (Strongly agree).
measure: Change in health literacy
time frame: 2 months, 12 months
description: The Health literacy questionnaire (HLQ) has nine scale scores that each measure an aspect of the multidimensional construct of health literacy. Each score provides insight into the strengths and limitations of the respondent, but the scores are most powerful when viewed together to show the 'health literacy profile' of the respondent.
measure: Patient knowledge, skill, and confidence for self-management.
time frame: 6 months
description: The Patient Activation Measure (PAM-13) comprises 13 items assessing patient knowledge, skill and confidence for self-management. Respondents indicate their agreement with statements on a 5-point Likert scale ranging from 1 (Strongly Disagree) to 4 (Strongly agree), or 5 (not applicable). Patients with a high activation score were associated with fewer mental health symptoms, greater recovery attitudes and medication adherence.
measure: Change in beliefs and perceptions about medicines and treatment
time frame: 2 months, 6 months, 12 months
description: The Beliefs about Medicines Questionnaire (BMQ) assesses beliefs and perceptions about medicines and treatment. The BMQ comprises two sections: the BMQ-Specific which assesses representations of medication prescribed for personal use and the BMQ-General which assesses beliefs about medicines in general. The two sections of the BMQ can be used in combination or separately. For this study, the BMQ-Specific will be used. Respondents rate 11 items on a 5-point scale ranging from 1 (strongly agree) to 5 (strongly disagree).
measure: Change in self-reported adherence to medicines
time frame: 2 months, 6 months, 12 months
description: The Medication Adherence Report Scale (MARS-5) measures self-reported adherence to medicines, it assesses both intentional and unintentional non-adherence. Respondents indicate their agreement with statements about their medicine use on a 5 point Likert scale ranging from 1 (always) to 5 (never).
measure: Change in medication use
time frame: 2 months, 6 months, 12 months
description: Data related to consumption of prescribed medication are identified through national prescription registries. The registries cover all prescriptions dispensed at pharmacies nationwide. The registries also include information about date of dispensation, quantity and strength dispensed. This will serve as complimentary information to patients' self-reported adherence.
measure: Health care utilization
time frame: Up to 24 months
description: Healthcare utilization will be assessed during follow-up, including patients' use of primary care services (general practitioner visits) and secondary care services (inpatient admissions and outpatient visits). The data source will be nationwide registries. The measurement unit will be mean number of visits.
measure: Health care (associated) costs
time frame: Up to 24 months
description: Health care (associated) costs will be valued using the tariffs of national agreements between the professional associations of medical specialists and the National Health Services. In secondary care, inpatient admissions and outpatient visits will be valued using the tariffs of the national case-mix system of the diagnosis-related groupings (DRG) and the ambulatory grouping system (DAGS). In addition, data will be collected on prescription of medication, which will be valued using the retail price. The data source will be nationwide registries. The measurement unit will be mean costs in Euros.
measure: Time to readmission to hospital
time frame: 30-days, 3 months, 6 months, 12 months, up to 10 years
description: Cardiac and all cause readmissions
measure: Time to death
time frame: 30-days, 3 months, 6 months, 12 months, up to 10 years
description: Cardiac and all cause mortality
measure: Change in anxiety and depression
time frame: 2 months, 6 months, 12 months
description: The Hospital Anxiety and Depression Scale (HADS). The HADS is a fourteen item scale where seven of the items relate to anxiety and seven relate to depression. The respondent rates each item on a 4-point scale ranging from 0 (absence) to 3 (extreme presence). The total score is 42 (21 per subscale).
measure: Change in self-reported health
time frame: 2 months, 6 months, 12 months
description: EQ-5D-5L is an 5 item (plus a VAS scale) self-report-questionnaire assessing self-reported health. Each question has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
measure: Change in chest pain
time frame: 2 months, 6 months, 12 months
description: The Seattle Angina Questionnaire (SAQ-7) comprises 7 dimensions of coronary artery disease. Each scale is transformed to a score of 0 to 100, where higher scores indicate better function (eg, less physical limitation, less angina, and better quality of life).
measure: Change in fatigue
time frame: 2 months, 6 months,12 months
description: A visual analog scale ranging from 0 (fatigue is not a problem) to 10 (fatigue is a major problem) is used to measure change in fatigue
measure: Frailty status
time frame: 12 months
description: The Study of Osteoporotic Fractures (SOF) index will be used to measure frailty status. The SOF index includes three items: 1) weight loss > 5% in the last year, 2) inability to rise from a chair five times without using arms, and 3) reduced energy level. The questions have dichotomous response alternatives (yes/no). Patients who meet none of these criteria will be considered robust, one of the criteria are pre-frail, and two or three of these criteria are considered frail.
measure: Patient preferences in discrete choice experiments
time frame: 3 months
description: A discrete choice experiment (DCE) is a quantitative technique for eliciting preferences to be used in the absence of revealed preference data. This involves asking individuals to state their preference over hypothetical alternative scenarios. Each alternative is described by several attributes which are used to determine if preferences are significantly influenced by these. No standardized measurement tool is used in DCE. The alternative scenarios (attributes) are developed for each individual study. Therefore, a DCE will be undertaken as a cross-sectional survey to investigate the preferences for aftercare. Participants are asked to choose between hypothetical aftercare programs described by five key characteristics that varies across each of the respondents' choices. The DCE will be carried out according to recommendations by the ISPOR group. A multinomial mixed logit model are used to model preferences and calculate marginal rates of substitution.
measure: Health related quality of life
time frame: 12 months
description: The HeartQoL questionnaire is a core ischemic heart disease specific health related quality of life (HRQL) questionnaire. The questionnaire comprises 14-items with 10-item physical and 4-item emotional subscales which are scored from 0 (poor HRQL) to 3 (better HRQL) with a global score if needed.
measure: Change in physical and mental dimensions of health.
time frame: 2 months, 6 months, 12 months
description: RAND-12 measures physical and mental dimensions of health. The 12 items in the questionnaire correspond to eight principal physical and mental health domains. The 12 items are summarized into two scores, a "Physical Health Summary Measure {PCS-physical component score}" and a "Mental Health Summary Measure {MCS-mental component score}".
measure: Change in health status following myocardial infarction
time frame: 2 months, 6 months, 12 months
description: The Myocardial Infarction Dimensional Assessment Scale (MIDAS) is a PRO measure developed and validated to specifically measure the health status of individuals who have suffered a myocardial infarction. It consist of 7 domains, and is a 35 item scale where respondents rate each item on a 5-point scale ranging from 1 (never) to 5 (always). The function of the MIDAS is to indicate the extent of ill health in each of the seven domains assessed, therefore each dimension is scored separately using a simple scoring methodology.
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Tone M Norekvål, PhD
role: Principal Investigator
affiliation: Haukeland University Hospital
last name: Tone M Norekvål, PhD
phone: +4799044635
email: tone.merete.norekval@helse-bergen.no
last name: Nina B Fålun, MSc
phone: +4790858527
email: nina.falun@helse-bergen.no
facility: 
status: Completed
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
country: Denmark
country: Norway
url: https://helse-bergen.no/en/procard/projects-in-procard/concard-pci
description: Study website
responsible party type: Sponsor
mesh term: Coronary Artery Disease
sharing ipd: No